Although ALK‐TKIs are effective and beneficial for the majority of EML4‐ALK+ NSCLC patients, there are patients who are more inhibitor‐insensitive, and there is a need for in‐depth research into the mechanisms that underpin innate drug resistance (Fig. 3). The gene discussed is ALK; the disease is non-small cell lung carcinoma.